Jun Chen

Dr. Jun Chen

Urology, Qilu Hospital of Shandong University, Jinan, Shandong, China
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2023 in Frontiers in Oncology
Verified
Journal Article
Open access
HLHao Liang
Hao Liang
YLYang Liu
Yang Liu
JGJiao Guo
Jiao Guo
MDMaoyang Dou
Maoyang Dou
XZXiaoyi Zhang
Xiaoyi Zhang
JCJun Chen
Jun Chen
Prostate cancer is one of the most common malignant cancers of the male genitourinary system and has high morbidity and mortality. Currently, treatment modalities for localized prostate cancer focus mainly on radical prostatectomy or radical radiation therapy. Some patients still experience disease recurrence or progression after these treatments, while others are already at an advanced stage or have metastases at the time of diagnosis. With the continuous development and progress of medicine in recent years, immunotherapy has become a revolutionary cancer treatment, and has achieved remarkable accomplishments in the treatment of hematologic malignancies. A variety of immunotherapies have also appeared in the field of advanced prostate cancer treatment, including therapeutic vaccines and immune checkpoint therapies. Despite the discrepancy between the results of some immunotherapy studies, immunotherapy for prostate cancer has shown some initial success, especially in combination immunotherapies. Currently, immunotherapy is mainly used in advanced prostate cancer, especially in patients with metastatic castration-resistant prostate cancer. However, with the development of more clinical trials of immunotherapy, more evidence will be provided supporting the rational application of immunotherapy in the future.

23 December 2024 in Annals of Medicine
Verified
Journal Article
Open access
HLHao Liang
Hao Liang
BZBin Zhou
Bin Zhou
PLPeixin Li
Peixin Li
XZXiaoyi Zhang
Xiaoyi Zhang
SZShijie Zhang
Shijie Zhang
JCJun Chen
Jun Chen
Increasing evidence indicates that cancer stem cells (CSCs) and cancer stem-like cells form a special subpopulation of cells that are ubiquitous in tumors. These cells exhibit similar characteristics to those of normal stem cells in tissues; moreover, they are capable of self-renewal and differentiation, as well as high tumorigenicity and drug resistance. In prostate cancer (PCa), it is difficult to kill these cells using androgen signaling inhibitors and chemotherapy drugs. Consequently, the residual prostate cancer stem cells (PCSCs) mediate tumor recurrence and progression. This review aims to provide a comprehensive and up-to-date overview of PCSCs, with a particular emphasis on potential therapeutic strategies targeting these cells. After searching in PubMed and Embase databases using 'prostate cancer' and 'cancer stem cells' as keywords, studies related were compiled and examined. In this review, we detail the origin and characteristics of PCSCs, introduce the regulatory pathways closely related to CSC survival and stemness maintenance, and discuss the link between epithelial-mesenchymal transition, tumor microenvironment and tumor stemness. Furthermore, we introduce the currently available therapeutic strategies targeting CSCs, including signaling pathway inhibitors, anti-apoptotic protein inhibitors, microRNAs, nanomedicine, and immunotherapy. Lastly, we summarize the limitations of current CSC research and mention future research directions. A deeper understanding of the regulatory network and molecular markers of PCSCs could facilitate the development of novel therapeutic strategies targeting these cells. Previous preclinical studies have demonstrated the potential of this treatment approach. In the future, this may offer alternative treatment options for PCa patients.

8 January 2024 in Urolithiasis
Verified
Journal Article
Closed access
PDF file
LHLiyong Hu
Liyong Hu
NZNianzhao Zhang
Nianzhao Zhang
XZXiaoyi Zhang
Xiaoyi Zhang
HLHao Liang
Hao Liang
YFYidong Fan
Yidong Fan
JCJun Chen
Jun Chen

1 January 2019 in Journal of Cancer
Verified
Journal Article
Open access
QYQingya Yang
Qingya Yang
JCJun Chen
Jun Chen
YZYaofeng Zhu
Yaofeng Zhu
ZXZhishun Xu
Zhishun Xu
Background: Mesenchymal stem cells (MSCs) have been proved to be able to differentiate into cells that are conducive to tumor growth and invasion. The mechanism is not clear. This present study was aimed to find out whether TGFβ1-Smad pathway was involved in this process. Methods: For the in vitro experiment, five groups of MSCs were cultured to test whether VX2 culture supernatant could induce the differentiation of MSCs into myofibroblasts. And then transforming growth factor β1(TGFβ1) receptor or Smad2 of MSCs were blocked by RNA interference technique to test whether TGFβ1-Smad pathway was involved in the differentiation. In the animal experiment, different kinds of MSCs were co-inoculated with VX2 cells in bladder to test whether the blockage of TGFβ1 receptor or Smad2 of MSCs could affect the expression of TGFβ1, epidermal growth factor (EGF), fibroblast activation protein alpha (FAPa), and matrix metalloprotein 9 (MMP9) in five animal groups. Results: VX2 culture supernatant could up-regulate the expression of α-SMA and Vimentin in MSCs, which indicated that VX2 culture supernatant could induce the differentiation of MSCs into myofibroblasts. Either the Blockage of TGFβ1 receptor or Smad2 of MSCs could lead to decreased expression of α-SMA and Vimentin in MSCs. In the animal experiment, MSCs could favor VX2 bladder tumor growth and up-regulate the expression of TGFβ1, EGF, FAPa, MMP9 in VX2 tumor tissue. However, when TGFβ1 receptor or Smad2 of MSCs was blocked, the above effects were attenuated. Conclusions: Under the induction of tumor microenvironment, MSCs can differentiate into myofibroblasts and then affect tumor interstitial microenvironment remodeling. This process is mediated by TGFβ1-Smad2 pathway.

6 September 2023 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
HLHao Liang
Hao Liang
QYQingya Yang
Qingya Yang
YZYaozhong Zhang
Yaozhong Zhang
HSHui Sun
Hui Sun
QFQiang Fu
Qiang Fu
JCJun Chen
Jun Chen

19 July 2025 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PLPeixin Li
Peixin Li
SYShengwen Yao
Shengwen Yao
WQWenqiang Qi
Wenqiang Qi
HLHanwen Liu
Hanwen Liu
XZXiaoyi Zhang
Xiaoyi Zhang
JLJingchao Liu
Jingchao Liu
Ferroptosis is an iron‐dependent form of regulated cell death. Previous research indicates that inducing ferroptosis holds significant promise in cancer therapy, particularly for patients who have failed traditional treatments. However, the presence of a ferroptosis escape mechanism in bladder cancer remains unclear, and the therapeutic potential of ferroptosis induction in this context requires further exploration. In this study, bioinformatics analyses and immunohistochemical staining revealed that FADS2 is aberrantly overexpressed in bladder cancer, with its high expression correlating with poor prognosis. Both in vivo and in vitro experiments, including CCK‐8 assays, lipid peroxidation assays, iron measurements and ferroptosis‐related gene analyses, demonstrated that silencing FADS2 can trigger ferroptosis in bladder cancer cells. Mechanistically, inhibition of the mTOR pathway and SREBP activity was found to reduce FADS2 expression and promote ferroptosis in bladder cancer. In conclusion, this study identifies a critical gene involved in ferroptosis escape in bladder cancer and suggests that FADS2 could serve as a novel prognostic marker and therapeutic target.